Autolus Therapeutics announces collaboration with Cabaletta Bio for use of Autolus’ safety switch system in cell therapies for autoimmune disease

Autolus Therapeutics, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has announced that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA). The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety switch into a cell therapy program for the treatment of autoimmune disease, with an option for Cabaletta to incorporate the safety switch in up to four additional cell therapy programs.

Read more from Autolus here.